← Back to Clinical Trials
Recruiting NCT06437665

NCT06437665 Tech-wise Driver (Technology Acceptance of Targeted ADAS for Older Adults)

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06437665
Status Recruiting
Phase
Sponsor Western University, Canada
Condition Older Adults
Study Type INTERVENTIONAL
Enrollment 68 participants
Start Date 2025-02-01
Primary Completion 2025-07-31

Eligibility & Interventions

Sex All sexes
Min Age 65 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
The intervention name in this study is ADAS-integrated driver simulation training.

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 68 participants in total. It began in 2025-02-01 with a primary completion date of 2025-07-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The tech-wise driver: Exploring the sustained efficacy and technology acceptance of targeted ADAS for older drivers A significant percentage of road traffic fatalities registered in Canada occurred among older adults. According to the studies, the Advanced Driver Assistance Systems (ADAS) can enhance the safety and mitigate the age-related declines of older drivers. Whether sustained use results in declines in driving performance in older drivers relying on ADAS remains largely unexplored. This is problematic given emerging evidence on ADAS use by older drivers. Furthermore, exploring changes in ADAS technology acceptance in relation to sustained use can inform the correlation between perceived safety and intention to use. The investigators hypothesize that, compared to driving simulator training alone, lane departure warning (LDW), cruise control (CC), and forward proximity warning (FPW) technology will result in a sustained decrease of critical driving errors in this population; and that exposure to the technology will increase participants' perceived usability and ease of use. To achieve this goal, the investigators will explore the determination of sustained efficacy, establish the impact of technology exposure, evaluate the concurrent validity of a computerized model of driving error type and severity using trained occupational therapy in-vehicle evaluation as the criterion, when evaluating older drivers 'performance. Our findings may significantly impact the ability of older drivers to choose in-vehicle technologies, and our study will be the first to assess the criterion validity of a simulator-derived computerized model against the findings of an evaluator-based functional assessment.

Eligibility Criteria

Inclusion Criteria: * Must be 65 years of age or older. * Must hold a valid driver's license. Exclusion Criteria: * Neurological or psychiatric conditions that would preclude driving * Use of psychotropic medications that may have a sustained negative impact on mental and/or physical functioning

Contact & Investigator

Central Contact

Liliana Alvarez, PhD

✉ lalvare2@uwo.ca

📞 519-6612111

Principal Investigator

Liliana Alvarez, PhD

PRINCIPAL INVESTIGATOR

Western University, Canada

Frequently Asked Questions

Who can join the NCT06437665 clinical trial?

This trial is open to participants of all sexes, aged 65 Years or older, studying Older Adults. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06437665 currently recruiting?

Yes, NCT06437665 is actively recruiting participants. Contact the research team at lalvare2@uwo.ca for enrollment information.

Where is the NCT06437665 trial being conducted?

This trial is being conducted at London, Canada.

Who is sponsoring the NCT06437665 clinical trial?

NCT06437665 is sponsored by Western University, Canada. The principal investigator is Liliana Alvarez, PhD at Western University, Canada. The trial plans to enroll 68 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology